. Dans-deux-cas, il s'agissait d'une éruption généralisée, dans un cas, l'éruption atteignait le décolleté et le visage avec un oedème (grade 2) Dans les 3 cas, il n'y avait pas de perturbation de bilan hépatorénal

C. Mateus and C. Robert, Effets cutan??s des nouvelles mol??cules utilis??es en canc??rologie, La Revue de M??decine Interne, vol.30, issue.5, pp.401-410, 2009.
DOI : 10.1016/j.revmed.2009.02.001

J. Blay, Th??rapeutiques antiangiog??niques des??tumeurs solides, La Revue de M??decine Interne, vol.28, pp.7-8, 2007.
DOI : 10.1016/j.revmed.2007.03.021

P. Fergelot, N. Rioux-leclercq, and J. Patard, Voies moléculaires de l'angiogenèse tumorale et nouvelles approches thérapeutiques ciblées dans le cancer du rein, Prog. Urol, vol.15, pp.1021-1029, 2005.

A. Lipworth, C. Robert, and A. Zhu, Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib, Oncology, vol.77, issue.5, pp.257-271, 2009.
DOI : 10.1159/000258880

F. Eskens and J. Verweij, The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review, European Journal of Cancer, vol.42, issue.18, pp.3127-3139, 2006.
DOI : 10.1016/j.ejca.2006.09.015

T. Kamba, B. Tam, H. Hashizume, A. Haskell, B. Sennino et al., VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature, American Journal of Physiology-Heart and Circulatory Physiology, vol.290, issue.2, pp.560-576, 2006.
DOI : 10.1016/S0002-9440(10)62567-9

A. Méjean and T. Lebret, Angiogen??se : l???exemple du cancer r??nal, Progr??s en Urologie, vol.18, pp.309-314, 2008.
DOI : 10.1016/S1166-7087(08)74559-7

S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas et al., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nature Reviews Drug Discovery, vol.47, issue.10, pp.835-844, 2006.
DOI : 10.4161/cc.3.2.648

A. Alavi, J. Hood, R. Frausto, D. Stupack, and D. Cheresh, Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli, Science, vol.301, issue.5629, pp.94-96, 2003.
DOI : 10.1126/science.1082015

B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-134, 2007.
DOI : 10.1056/NEJMoa060655

J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-390, 2008.
DOI : 10.1056/NEJMoa0708857

V. Boige, J. Barbare, and O. Rosmorduc, Utilisation du soraf??nib (Nexavar??) dans le traitement du carcinome h??patocellulaire??: recommandations Prodige Afef, Gastroent??rologie Clinique et Biologique, vol.32, issue.1, pp.3-7, 2008.
DOI : 10.1016/j.gcb.2007.11.001

D. Lago, L. , D. Hondt, V. Awada, and A. , Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors, The Oncologist, vol.13, issue.8, pp.845-858, 2008.
DOI : 10.1634/theoncologist.2007-0233

H. Richly, B. Schultheis, I. Adamietz, P. Kupsch, M. Grubert et al., Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial, European Journal of Cancer, vol.45, issue.4, pp.579-587, 2009.
DOI : 10.1016/j.ejca.2008.10.039

T. Eisen, T. Ahmad, K. Flaherty, M. Gore, S. Kaye et al., Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis, British Journal of Cancer, vol.24, issue.16, pp.581-586, 2006.
DOI : 10.1038/sj.onc.1208841

A. Hauschild, S. Agarwala, U. Trefzer, D. Hogg, C. Robert et al., Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma, Journal of Clinical Oncology, vol.27, issue.17, pp.2823-2830, 2009.
DOI : 10.1200/JCO.2007.15.7636

D. Mcdermott, J. Sosman, R. Gonzalez, F. Hodi, G. Linette et al., Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group, Journal of Clinical Oncology, vol.26, issue.13, pp.2178-2185, 2008.
DOI : 10.1200/JCO.2007.14.8288

M. Streit and M. Detmar, Angiogenesis, lymphangiogenesis and melanoma metastasis, Oncogene, vol.22, issue.20, pp.3172-3179, 2003.
DOI : 10.1073/pnas.93.25.14765

URL : http://www.nature.com/onc/journal/v22/n20/pdf/1206457a.pdf

S. Sherman, Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, pp.1493-1499, 2009.
DOI : 10.1210/jc.2008-0923

J. Aragon-ching and W. Dahut, VEGF Inhibitors and Prostate Cancer Therapy, Current Molecular Pharmacology, vol.2, issue.2, pp.161-168, 2009.
DOI : 10.2174/1874467210902020161

URL : http://europepmc.org/articles/pmc2711630?pdf=render

H. Burris and C. Rocha-lima, New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways, The Oncologist, vol.13, issue.3, pp.289-298, 2008.
DOI : 10.1634/theoncologist.2007-0134

C. Gridelli, P. Maione, D. Gaizo, F. Colantuoni, G. Guerriero et al., Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer, The Oncologist, vol.12, issue.2, pp.191-200, 2007.
DOI : 10.1634/theoncologist.12-2-191

G. Blumenschein, U. Gatzemeier, F. Fossella, D. Stewart, L. Cupit et al., Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.26, pp.4274-4280, 2009.
DOI : 10.1200/JCO.2009.22.0541

V. Echeverria, S. Burgess, J. Gamble-george, R. Zeitlin, X. Lin et al., Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice, Neuroscience, vol.162, issue.4, pp.1220-1231, 2009.
DOI : 10.1016/j.neuroscience.2009.05.019

J. Autier, C. Mateus, J. Wechsler, A. Spatz, and C. Robert, Effets secondaires cutan??s du sorafenib et du sunitinib, Annales de Dermatologie et de V??n??r??ologie, vol.135, issue.2, pp.148-153, 2008.
DOI : 10.1016/j.annder.2007.12.006

J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert, Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor, Archives of Dermatology, vol.144, issue.7, pp.886-892, 2008.
DOI : 10.1001/archderm.144.7.886

M. Bennani-lahlou, C. Mateus, B. Escudier, C. Massard, J. Soria et al., N??vus ??ruptifs sous soraf??nib, Annales de Dermatologie et de V??n??r??ologie, vol.135, issue.10, pp.672-674, 2008.
DOI : 10.1016/j.annder.2008.04.016

H. Kong, V. Sibaud, C. Turner, M. Fojo, T. Hornyak et al., Sorafenibinduced eruptive melanocytic lesions, Arch Dermatol, vol.144, pp.820-822, 2008.
DOI : 10.1001/archderm.144.6.820

URL : http://europepmc.org/articles/pmc2556207?pdf=render

M. Lacouture, A. Desai, K. Soltani, V. Petronic-rosic, A. Laumann et al., Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor, Clinical and Experimental Dermatology, vol.31, issue.6, pp.783-785, 2006.
DOI : 10.1016/S0190-9622(99)70488-3

H. Kong, E. Cowen, N. Azad, W. Dahut, M. Gutierrez et al., Keratoacanthomas associated with sorafenib??therapy, Journal of the American Academy of Dermatology, vol.56, issue.1, pp.171-172, 2007.
DOI : 10.1016/j.jaad.2006.10.032

URL : http://europepmc.org/articles/pmc1781060?pdf=render

D. Hong, S. Reddy, V. Prieto, J. Wright, N. Tannir et al., Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib, Archives of Dermatology, vol.144, issue.6, pp.779-782, 2008.
DOI : 10.1001/archderm.144.6.779

J. Arnault, J. Wechsler, B. Escudier, A. Spatz, G. Tomasic et al., Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib, Journal of Clinical Oncology, vol.27, issue.23, pp.59-61, 2009.
DOI : 10.1200/JCO.2009.23.4823

E. Kwon, L. Kish, and C. Jaworsky, The histologic spectrum of epithelial neoplasms induced by sorafenib, Journal of the American Academy of Dermatology, vol.61, issue.3, pp.522-527, 2009.
DOI : 10.1016/j.jaad.2008.10.043

H. Jantzem, D. Dupre-goetghebeur, P. Spindler, and J. Merrer, K??ratoacanthomes multiples ??ruptifs induits par le soraf??nib, Annales de Dermatologie et de V??n??r??ologie, vol.136, issue.12, pp.894-897, 2009.
DOI : 10.1016/j.annder.2009.09.010

J. Macgregor, D. Silvers, M. Grossman, and W. Sherman, Sorafenib-induced erythema multiforme, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.527-528, 2007.
DOI : 10.1016/j.jaad.2006.10.981

R. Feltes, F. Rodríguez, M. González-beato, and M. , Erythema multiforme induced by sorafenib, Clinical and Experimental Dermatology, vol.56, issue.7, pp.368-369, 2009.
DOI : 10.1111/j.1365-2230.2009.03320.x

C. Bilaç, T. Müezzino?lu, A. Ermertcan, T. Kayhan, G. Temelta? et al., Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma, Cutaneous and Ocular Toxicology, vol.28, issue.2, pp.90-92, 2009.
DOI : 10.1016/j.jaad.2006.10.981

C. Wolber, A. Udvardi, G. Tatzreiter, A. Schneeberger, and B. Volc-platzer, Perforating folliculitis, angioedema, hand-foot syndrome ?????? multiple cutaneous side effects in a patient treated with sorafenib, Journal der Deutschen Dermatologischen Gesellschaft, vol.4, issue.3, pp.449-452, 2009.
DOI : 10.1111/j.1610-0387.2009.07017.x

N. Chung, M. Gutierrez, and M. Turner, Leukocytoclastic Vasculitis Masquerading as Hand-Foot Syndrome in a Patient Treated With Sorafenib, Archives of Dermatology, vol.142, issue.11, pp.1510-1511, 2006.
DOI : 10.1001/archderm.142.11.1510

A. Richetta, E. Maiani, V. Carboni, V. Carlomagno, M. Cimillo et al., Sorafenib: atypical cutaneous side effects, Eur J Dermatol, vol.17, pp.549-550, 2007.

M. Frigerio, V. Santi, D. Micoli, A. Trevisani, and F. , Hyperkeratosis of nipple skin during sorafenib treatment, Digestive and Liver Disease, vol.41, issue.8, p.611, 2009.
DOI : 10.1016/j.dld.2009.02.001

D. Strumberg, A. Awada, H. Hirte, J. Clark, S. Seeber et al., Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?, European Journal of Cancer, vol.42, issue.4, pp.548-556, 2006.
DOI : 10.1016/j.ejca.2005.11.014

B. Vincenzi, D. Santini, A. Russo, R. Addeo, F. Giuliani et al., Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib, The Oncologist, vol.15, issue.1, pp.85-92, 2010.
DOI : 10.1634/theoncologist.2009-0143

W. Lee, J. Lee, S. Chang, M. Lee, Y. Kang et al., Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib, British Journal of Dermatology, vol.347, issue.5, pp.1045-1051, 2009.
DOI : 10.1111/j.1365-2133.2009.09290.x

C. Robert, S. Faivre, R. E. , A. J. Escudier, and B. , Subungual Splinter Hemorrhages: A Clinical Window to Inhibition of Vascular Endothelial Growth Factor Receptors?, Annals of Internal Medicine, vol.143, issue.4, pp.313-314, 2005.
DOI : 10.7326/0003-4819-143-4-200508160-00021

C. Robert, J. Soria, A. Spatz, L. Cesne, A. Malka et al., Cutaneous side-effects of kinase inhibitors and blocking antibodies, The Lancet Oncology, vol.6, issue.7, pp.491-500, 2005.
DOI : 10.1016/S1470-2045(05)70243-6

S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic et al., Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer, Journal of Clinical Oncology, vol.24, issue.1, pp.25-35, 2006.
DOI : 10.1200/JCO.2005.02.2194

R. Kerbel and J. Folkman, Clinical translation of angiogenesis inhibitors, Nature Reviews Cancer, vol.17, issue.10, pp.727-739, 2002.
DOI : 10.3109/08977199909103521

R. Motzer, T. Hutson, P. Tomczak, M. Michaelson, R. Bukowski et al., Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.27, issue.22, pp.3584-3590, 2009.
DOI : 10.1200/JCO.2008.20.1293

G. Demetri, A. Van-oosterom, C. Garrett, M. Blackstein, M. Shah et al., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, The Lancet, vol.368, issue.9544, pp.1329-1338, 2006.
DOI : 10.1016/S0140-6736(06)69446-4

G. Papaetis and K. Syrigos, Sunitinib, BioDrugs, vol.27, issue.2, pp.377-389, 2009.
DOI : 10.7326/0003-4819-145-9-200611070-00008

H. Burstein, A. Elias, H. Rugo, M. Cobleigh, A. Wolff et al., Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane, Journal of Clinical Oncology, vol.26, issue.11, pp.1810-1816, 2008.
DOI : 10.1200/JCO.2007.14.5375

S. Nguyen, M. Franklin, and A. Dudek, Skin ulcers in Klippel???Trenaunay syndrome respond to sunitinib, Translational Research, vol.151, issue.4, pp.194-196, 2008.
DOI : 10.1016/j.trsl.2008.01.002

G. Sonpavde, P. Periman, D. Bernold, D. Weckstein, M. Fleming et al., Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy, Annals of Oncology, vol.25, issue.5, pp.319-324, 2010.
DOI : 10.1007/s10637-007-9050-y

URL : https://academic.oup.com/annonc/article-pdf/21/2/319/929873/mdp323.pdf

D. Michaelson, M. Regan, M. Oh, W. Kaufman, D. Olivier et al., Phase II study of sunitinib in men with advanced prostate cancer, Annals of Oncology, vol.86, issue.3, pp.913-920, 2009.
DOI : 10.1210/jc.86.3.1341

M. Preusser, M. Hutterer, M. Sohm, O. Koperek, K. Elandt et al., Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate, Journal of Neuro-Oncology, vol.37, issue.2, pp.305-308, 2010.
DOI : 10.1007/s11060-009-0027-x

I. Song, J. Lim, H. Yun, S. Kim, D. Kang et al., Biochemical and Pathological Response of Prostate Cancer in a Patient with Metastatic Renal Cell Carcinoma on Sunitinib Treatment, Japanese Journal of Clinical Oncology, vol.361, issue.20 May Suppl, pp.833-836, 2009.
DOI : 10.1016/S0140-6736(03)13554-4

H. Mackay, A. Tinker, E. Winquist, G. Thomas, K. Swenerton et al., A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184, Gynecologic Oncology, vol.116, issue.2, pp.163-167, 2010.
DOI : 10.1016/j.ygyno.2009.08.012

M. Hensley, M. Sill, D. Scribner, J. Brown, R. Debernardo et al., Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study, Gynecologic Oncology, vol.115, issue.3, pp.460-465, 2009.
DOI : 10.1016/j.ygyno.2009.09.011

R. Motzer, T. Hutson, P. Tomczak, M. Michaelson, R. Bukowski et al., Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-124, 2007.
DOI : 10.1056/NEJMoa065044

C. Robert, A. Spatz, S. Faivre, A. J. , and R. E. , Tyrosine kinase inhibition and grey hair, The Lancet, vol.361, issue.9362, p.1056, 2003.
DOI : 10.1016/S0140-6736(03)12805-X

K. Tsai, C. Yang, T. Kuo, H. Hong, and J. Chang, Hand-Foot Syndrome and Seborrheic Dermatitis-Like Rash Induced by Sunitinib in a Patient With Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.24, issue.36, pp.5786-5788, 2006.
DOI : 10.1200/JCO.2006.08.6868

B. Billemont, S. Barete, and O. Rixe, Scrotal cutaneous side effects of sunitinib, N. Engl. J. Med, vol.359, pp.975-976, 2008.

C. Durant, M. Saint-jean, J. Connault, M. Pistorius, and B. Planchon, Syndrome pied-main n??crotique sous antiangiog??niques chez une patiente porteuse d???une acropathie ulc??romutilante de Th??venard, Journal des Maladies Vasculaires, vol.34, issue.3, pp.222-225, 2009.
DOI : 10.1016/j.jmv.2009.01.001

S. Feyerabend, D. Schilling, C. Wicke, and A. Stenzl, Toxic Dermatolysis, Tissue Necrosis and Impaired Wound Healing due to Sunitinib Treatment Leading to Forefoot Amputation, Urologia Internationalis, vol.82, issue.2, pp.246-248, 2009.
DOI : 10.1159/000200809

G. Bar-sela, E. Kedem, S. Hadad, S. Pollack, N. Haim et al., Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Sunitinib in a Patient with a Gastrointestinal Stromal Tumor, Japanese Journal of Clinical Oncology, vol.97, issue.2, pp.163-165, 2010.
DOI : 10.1059/0003-4819-105-1-148

C. Dreyer, R. E. Faivre, and S. , Les th??rapies cibl??es et leurs indications dans les tumeurs solides, La Revue de M??decine Interne, vol.30, issue.5, pp.416-424, 2009.
DOI : 10.1016/j.revmed.2008.12.022

K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh et al., Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer, New England Journal of Medicine, vol.357, issue.26, pp.2666-2676, 2007.
DOI : 10.1056/NEJMoa072113

V. Gotlib, S. Khaled, I. Lapko, N. Mar, and M. Saif, Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response, Anti-Cancer Drugs, vol.17, issue.10, pp.1227-1229, 2006.
DOI : 10.1097/01.cad.0000231481.07654.fc

A. Munehiro, K. Yoneda, K. Nakai, T. Demitsu, T. Moriue et al., Bevacizumabinduced hand-foot syndrome: circumscribed type, Br. J. Dermatol, p.2010
DOI : 10.1111/j.1365-2133.2010.09716.x

L. Hueso, O. Sanmartín, E. Nagore, R. Botella-estrada, C. Requena et al., Chemotherapy-Induced Acral Erythema: A Clinical and Histopathologic Study of 44 Cases, Actas Dermo-Sifiliogr??ficas (English Edition), vol.99, issue.4
DOI : 10.1016/S1578-2190(08)70252-X

R. Zuehlke, Erythematous Eruption of the Palms and Soles Associated with Mitotane Therapy, Dermatology, vol.148, issue.2, pp.90-92, 1974.
DOI : 10.1159/000251603

J. Webster-gandy, C. How, and K. Harrold, Palmar???plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre, European Journal of Oncology Nursing, vol.11, issue.3, pp.238-246, 2007.
DOI : 10.1016/j.ejon.2006.10.004

M. Janusch, M. Fischer, W. Marsch, H. Holzhausen, T. Kegel et al., The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy, Eur J Dermatol, vol.16, pp.494-499, 2006.

Y. Lassere and P. Hoff, Management of hand-foot syndrome in patients treated with capecitabine (Xeloda??), European Journal of Oncology Nursing, vol.8, issue.1, pp.31-40, 2004.
DOI : 10.1016/j.ejon.2004.06.007

G. Wilkes and D. Doyle, Palmar-plantar erythrodysesthesia, Clin J Oncol Nurs, vol.9, pp.103-106, 2005.

D. Lorusso, D. Stefano, A. Carone, V. Fagotti, A. Pisconti et al., Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome), Annals of Oncology, vol.67, issue.6
DOI : 10.1093/annonc/mdl079

URL : https://academic.oup.com/annonc/article-pdf/18/7/1159/639500/mdl477.pdf

E. Lin, J. Morris, and G. Ayers, Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity, Oncology, vol.16, pp.31-37, 2002.

Y. Park, B. Ryoo, H. Lee, S. Kim, and J. Chung, High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy, Annals of Oncology, vol.14, issue.11, pp.1691-1692, 2003.
DOI : 10.1093/annonc/mdg446

U. Jacobi, E. Waibler, P. Schulze, J. Sehouli, G. Oskay-ozcelik et al., Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?, Annals of Oncology, vol.16, issue.7, pp.1210-1211, 2005.
DOI : 10.1002/lapl.200310028

D. Tsuruta, K. Mochida, T. Hamada, M. Ishii, K. Wakasa et al., Chemotherapy-induced acral erythema: report of a case and immunohistochemical findings. Clinical dermatology . Concise report, Clinical and Experimental Dermatology, vol.10, issue.5, pp.386-388, 2000.
DOI : 10.1001/archderm.122.9.1023

O. Lyass, B. Uziely, R. Ben-yosef, D. Tzemach, N. Heshing et al., Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma, Cancer, vol.13, issue.5, pp.1037-1047, 2000.
DOI : 10.1200/JCO.1995.13.4.996

K. Molpus, L. Anderson, C. Craig, and J. Puleo, The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma1, Gynecologic Oncology, vol.93, issue.2, pp.513-516, 2004.
DOI : 10.1016/j.ygyno.2004.02.019

G. Mangili, M. Petrone, C. Gentile, D. Marzi, P. Viganò et al., Prevention strategies in palmar???plantar erythrodysesthesia onset: The role of regional cooling, Gynecologic Oncology, vol.108, issue.2, pp.332-335, 2008.
DOI : 10.1016/j.ygyno.2007.10.021

B. Gerbrecht, Current Canadian Experience With Capecitabine, Cancer Nursing, vol.26, issue.2, pp.161-167, 2003.
DOI : 10.1097/00002820-200304000-00011

I. Yucel and G. Guzin, Topical henna for capecitabine induced hand???foot syndrome, Investigational New Drugs, vol.51, issue.2, pp.189-192, 2008.
DOI : 10.1515/znc-2004-7-803

N. Yoshimoto, T. Yamashita, T. Fujita, H. Hayashi, N. Tsunoda et al., Impact of prophylactic pyridoxine on occurrence of hand???foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer, Breast Cancer, vol.55, issue.4, p.2009
DOI : 10.1007/BF00216925

J. Brown, K. Burck, D. Black, and C. Collins, Treatment of cytarabine acral erythema with corticosteroids, Journal of the American Academy of Dermatology, vol.24, issue.6, pp.1023-1025, 1991.
DOI : 10.1016/S0190-9622(08)80126-0

D. Vail, R. Chun, D. Thamm, L. Garrett, A. Cooley et al., Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model, Clin. Cancer Res, vol.4, pp.1567-1571, 1998.

A. Werchniak, S. Chaffee, and J. Dinulos, Methotrexate-induced bullous acral erythema in a child, Journal of the American Academy of Dermatology, vol.52, issue.5, pp.93-95, 2005.
DOI : 10.1016/j.jaad.2004.11.065

R. Drake, W. Lin, M. King, D. Farrar, D. Miller et al., Oral dexamethasone attenuates Doxil??-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies, Gynecologic Oncology, vol.94, issue.2, pp.320-324, 2004.
DOI : 10.1016/j.ygyno.2004.05.027

I. Kara, B. Sahin, and M. Erkisi, Palmar-plantar erythrodysesthesia due to docetaxelcapecitabine therapy is treated with vitamin E without dose reduction, Breast, vol.15, pp.414-424, 2006.
DOI : 10.1016/j.breast.2005.07.007

E. Kingsley, 5-Fluorouracil Dermatitis Prophylaxis with a Nicotine Patch, Annals of Internal Medicine, vol.120, issue.9, p.813, 1994.
DOI : 10.7326/0003-4819-120-9-199405010-00025

. Www, has-sante.fr. XELODA. Site consulté le 10 mars, 2009.

M. Lacouture, S. Wu, C. Robert, M. Atkins, H. Kong et al., Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib, The Oncologist, vol.13, issue.9, pp.1001-1011, 2008.
DOI : 10.1634/theoncologist.2008-0131

D. Chu, M. Lacouture, T. Fillos, and S. Wu, Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis, Acta Oncologica, vol.13, issue.2, pp.176-186, 2008.
DOI : 10.1158/1078-0432.CCR-06-2328

D. Chu, M. Lacouture, E. Weiner, and S. Wu, Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non???Renal Cell Carcinoma: A Meta-analysis, Clinical Genitourinary Cancer, vol.7, issue.1, pp.11-19, 2009.
DOI : 10.3816/CGC.2009.n.002

J. Do and Y. Kim, Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand?foot syndrome?, Clinical and Experimental Dermatology, vol.73, issue.5, pp.519-521, 2007.
DOI : 10.1016/S0190-9622(00)90112-9

H. Rh, T. Kuzel, R. Anderson, D. West, and M. Lacouture, Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib : Impact on quality of life (QoL), J Clin Oncol, vol.26, 2008.

N. Azad, J. Aragon-ching, W. Dahut, M. Gutierrez, W. Figg et al., Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy, Clinical Cancer Research, vol.15, issue.4, pp.1411-1416, 2009.
DOI : 10.1158/1078-0432.CCR-08-1141

K. Flaherty and M. Brose, Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment, Clinical Cancer Research, vol.15, issue.24, p.7749, 2009.
DOI : 10.1158/1078-0432.CCR-09-1190

URL : http://clincancerres.aacrjournals.org/content/clincanres/15/24/7749.1.full.pdf

C. Yang, W. Lin, C. Chuang, Y. Chang, S. Pang et al., Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy, British Journal of Dermatology, vol.24, issue.3, pp.592-596, 2008.
DOI : 10.1111/j.1365-2133.2007.08357.x

S. Lai, T. Kuzel, and M. Lacouture, Hand-Foot and Stump Syndrome to Sorafenib, Journal of Clinical Oncology, vol.25, issue.3, pp.341-343, 2007.
DOI : 10.1200/JCO.2006.08.9565

L. Jain, E. Gardner, W. Figg, M. Chernick, and H. Kong, Lack of Association Between Excretion of Sorafenib in Sweat and Hand-Foot Skin Reaction, Pharmacotherapy, vol.30, issue.1, pp.52-56, 2010.
DOI : 10.1111/j.1365-2133.2007.08357.x

V. Sibaud, J. Delord, and C. Chevreau, Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?, Targeted Oncology, vol.1, issue.4, pp.307-310, 2009.
DOI : 10.1093/annonc/mdn389

S. Boone, G. Jameson, V. Hoff, D. Lacouture, and M. , Blackberry-induced hand-foot skin reaction to sunitinib, Investigational New Drugs, vol.143, issue.4, pp.389-390, 2009.
DOI : 10.7326/0003-4819-143-4-200508160-00021

H. Akaza, T. Tsukamoto, M. Murai, K. Nakajima, and S. Naito, Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma, Japanese Journal of Clinical Oncology, vol.37, issue.10, pp.755-762, 2007.
DOI : 10.1093/jjco/hym095

N. Van-erp, K. Eechoute, A. Van-der-veldt, J. Haanen, A. Reyners et al., Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity, Journal of Clinical Oncology, vol.27, issue.26, pp.4406-4412, 2009.
DOI : 10.1200/JCO.2008.21.7679

M. Beldner, M. Jacobson, G. Burges, D. Dewaay, J. Maize et al., Localized Palmar Plantar Epidermal Hyperplasia: A Previously Undefined Dermatologic Toxicity to Sorafenib, The Oncologist, vol.12, issue.10, pp.1178-1182, 2007.
DOI : 10.1634/theoncologist.12-10-1178

URL : http://theoncologist.alphamedpress.org/content/12/10/1178.full.pdf

M. Lacouture, L. Reilly, P. Gerami, and J. Guitart, Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib, Annals of Oncology, vol.11, issue.5, pp.1955-1961, 2008.
DOI : 10.1188/07.CJON.649-656

O. Bouché, E. Scaglia, Z. Reguiai, V. Singha, H. Brixi-benmansour et al., Bioth??rapies cibl??es en canc??rologie digestive??: prise en charge de leurs effets secondaires, Gastroent??rologie Clinique et Biologique, vol.33, issue.4, pp.306-322, 2009.
DOI : 10.1016/j.gcb.2009.02.008

M. Hütten, L. Lassay, B. Sachs, P. Deutz, R. Mertens et al., Successful Topical Treatment of Sorafenib-Induced Hand-Foot Skin Reaction in a Child with Hepatocellular Carcinoma, Pediatric Dermatology, vol.47, issue.3, pp.349-350, 2009.
DOI : 10.1111/j.1525-1470.2009.00933.x

M. Farhat, N. El-saghir, and A. Shamseddine, Hand-foot syndrome with docetaxel : A five-case series, Annals of Saudi Medicine, vol.28, issue.5, pp.374-377, 2008.
DOI : 10.4103/0256-4947.51691

G. Fitoussi, C. Paul, and C. Robert, La relation médecin-malade en dermatologie, Ann Dermatol Venereol, vol.124, pp.864-868, 1997.

N. Britten, Patients' demands for prescriptions in primary care, BMJ, vol.310, issue.6987, pp.1084-1085, 1995.
DOI : 10.1136/bmj.310.6987.1084

J. L. Stalder, L?????ducation th??rapeutique : un enjeu majeur en dermatologie, Annales de Dermatologie et de V??n??r??ologie, vol.132, issue.2, pp.111-113, 2005.
DOI : 10.1016/S0151-9638(05)79219-X

T. Boyé, F. Boralevi, C. Buzenet, C. Labrèze, and A. Taïeb, Education et dermatite atopique. L'expérience de l'unité de dermatologie pédiatrique du CHU de Bordeaux, Ann Dermatol Venereol, vol.130, pp.285-289, 2003.

P. Guyot-caquelin, F. Granel-brocard, J. Cuny, D. Spaeth, A. Barbaud et al., Ulc??rations des membres inf??rieurs sous sunitinib, Annales de Dermatologie et de V??n??r??ologie, vol.137, issue.10, p.2010
DOI : 10.1016/j.annder.2010.04.022

H. Shinzawa, A. Takeda, Y. Sone, K. Murashita, and E. Uchinuma, Wound healing process of a full-thickness skin wound model in rats, Int Surg, vol.92, issue.2, pp.63-72, 2007.

M. Zangari, L. Fink, F. Elice, F. Zhan, D. Adcock et al., Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents, Journal of Clinical Oncology, vol.27, issue.29, pp.4865-4873, 2009.
DOI : 10.1200/JCO.2009.22.3875